PHARMACYTE BIOTECH, INC. (PMCB) Operating cash flow 2017–2026
PHARMACYTE BIOTECH, INC. (PMCB) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$5.2MFY2026 · since FY2017: -$3.3M → -$5.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$5.2M | -73.0% |
| FY2025 | -$3.0M | -38.4% |
| FY2024 | -$2.2M | +43.3% |
| FY2023 | -$3.8M | +7.9% |
| FY2022 | -$4.1M | -23.6% |
| FY2021 | -$3.3M | -42.4% |
| FY2020 | -$2.3M | +18.7% |
| FY2019 | -$2.9M | +43.3% |
| FY2018 | -$5.1M | -52.1% |
| FY2017 | -$3.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PMCB financial trends
PMCB RevenuePMCB Net incomePMCB Net marginPMCB Gross profitPMCB Gross marginPMCB Operating incomePMCB Operating marginPMCB Free cash flowPMCB Capital expendituresPMCB Return on equityPMCB Stock buybacksPMCB Dividends paidPMCB Total assetsPMCB Total liabilitiesPMCB Shareholders’ equityPMCB overview →